A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

NCT03513666 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

COMBINATION_PRODUCT: Drug intervention

Sponsor

Shanghai Junshi Bioscience Co., Ltd.